Peptides for
Cognitive Performance

The brain's energy crisis is a NAD+ crisis. Neurons are post-mitotic cells — they cannot easily be replaced when they die — and they depend almost entirely on oxidative phosphorylation for their ATP supply. Every step of this process requires NAD+ as an electron carrier. As NAD+ levels decline with age, the rate-limiting step in neuronal energy production slows, and the consequences manifest as the characteristic cognitive fatigue, brain fog, and reduced processing speed of aging.

NAD+ restoration addresses this at the source. By repleting the NAD+ pool in neural tissue, mitochondrial Complex I activity recovers, ATP production normalizes, and neurons regain the metabolic capacity to sustain high-frequency synaptic firing — the substrate of focus, working memory, and executive function.

But the energy story is only part of NAD+'s cognitive role. SIRT1 — the most extensively studied member of the sirtuin family of NAD+-dependent deacetylases — is one of the brain's most important neuroprotective proteins. SIRT1 deacetylates and regulates p53 (reducing apoptosis under mild stress), NF-κB (reducing neuroinflammatory signaling), and multiple transcription factors governing synaptic plasticity. When NAD+ levels fall, SIRT1 activity falls proportionally — removing a critical layer of neural protection precisely when the brain needs it most.

A third mechanism deserves attention: PARP1 competition. PARP1 is a DNA repair enzyme that consumes NAD+ at a high rate during oxidative stress. In an aging brain subject to chronic oxidative damage, PARP1 hyperactivation creates a catastrophic NAD+ drain — depleting the pool needed for SIRT1 activity and mitochondrial function. NAD+ supplementation replenishes this pool, allowing both repair and protective functions to proceed simultaneously rather than competing for a shrinking resource.

Epithalon (also rendered as Epitalon) is a tetrapeptide — Ala-Glu-Asp-Gly — originally isolated from the pineal gland extract used in Khavinson's foundational work on peptide bioregulators. Its cognitive relevance operates through two distinct but interrelated mechanisms: telomerase activation in neural tissue, and restoration of pineal gland function.

The telomere angle is perhaps the most fundamental. Telomere shortening in neural progenitor cells and glial cells is now recognized as a driver of cognitive aging and increased neurodegenerative disease risk. Epithalon activates telomerase — the enzyme that synthesizes new telomeric DNA — across multiple tissue types. In neural tissue, this translates to reduced cellular senescence, improved progenitor cell viability, and extended functional lifespan of neurons and supporting glial cells.

The pineal gland connection is equally important for daily cognitive performance. The pineal gland (epiphysis) is the primary source of melatonin — the neuroendocrine signal that governs circadian rhythm and sleep architecture. With age, the pineal gland undergoes calcification and functional decline, reducing melatonin output and progressively disrupting sleep architecture. Deep slow-wave sleep — the stage most critical for hippocampal memory consolidation and glymphatic clearance of toxic neural waste products including amyloid-beta and tau protein — is the first casualty of pineal dysfunction.

Epithalon directly stimulates pineal gland activity and restores melatonin regulatory capacity. Users consistently report dramatically improved sleep depth and architecture. The cognitive downstream effects — better memory consolidation, improved learning capacity, enhanced mood stability — follow predictably from restored sleep quality. For cognitive performance, optimizing sleep architecture may be the single highest-leverage intervention available, and Epithalon addresses it at the glandular level rather than through pharmacological sedation.

Growth hormone's cognitive relevance is substantially underappreciated outside specialized research circles. GH itself has some central nervous system effects — GH receptors are expressed throughout the brain, and GH deficiency produces well-documented cognitive symptoms including impaired memory, reduced processing speed, and depression. But the primary mediator of GH's neurotrophic effects is IGF-1 (Insulin-like Growth Factor 1), which GH stimulates in both the liver and, critically, in the brain itself.

IGF-1 crosses the blood-brain barrier with relative efficiency and binds IGF-1 receptors distributed throughout the cortex, hippocampus, cerebellum, and brainstem. The consequences of IGF-1 receptor activation in neural tissue are extensive: neuroprotection against apoptosis, promotion of dendritic arborization (the branching of neural connections), enhancement of myelination, and potent upregulation of BDNF expression. The BDNF connection is particularly significant — BDNF is often described as "fertilizer for the brain," and sustained IGF-1 elevation is one of the most reliable ways to maintain BDNF expression as BDNF-stimulating behaviors (intense exercise, caloric restriction, novel learning) become more difficult with age.

CJC-1295 (a long-acting GHRH analogue) and Ipamorelin (a selective ghrelin mimetic) work through complementary receptors to produce a amplified, clean GH pulse. Administered together at night 30–60 minutes before sleep, they synchronize with the natural GH secretion that peaks during slow-wave sleep — amplifying rather than disrupting the physiological pattern. This timing is not incidental: slow-wave sleep is simultaneously the window of maximum GH secretion and maximum neural repair, memory consolidation, and glymphatic waste clearance. Amplifying the GH pulse during this window optimizes all of these processes concurrently.

The combination of elevated IGF-1 throughout the day and amplified GH during deep sleep produces a sustained neurotrophic environment that addresses both the metabolic maintenance of existing neural circuits and the formation of new ones.

BPC-157 is best known in performance circles for its musculoskeletal healing properties — but its neuroprotective and neuroregenerative profile is substantial and mechanistically distinct. For cognitive performance, the most relevant properties are its anti-neuroinflammatory effects, its documented ability to support recovery of damaged monoaminergic pathways, and emerging evidence for BBB-crossing activity.

Neuroinflammation — driven by chronically activated microglia releasing pro-inflammatory cytokines — is one of the primary suppressors of cognitive performance in both acute stress states and chronic aging. BPC-157 modulates microglial activation and cytokine release, reducing the inflammatory tone in neural tissue without the systemic immunosuppression associated with pharmaceutical anti-inflammatory agents. This creates a more permissive environment for synaptic plasticity, BDNF expression, and neurogenesis — all of which are suppressed by neuroinflammatory signaling.

Perhaps the most compelling cognitive application of BPC-157 is its documented effect on monoaminergic pathways. Chronic psychological stress, trauma, and sustained oxidative damage progressively impair dopaminergic and serotonergic transmission — the neural circuits governing motivation, executive function, mood regulation, and sustained attention. BPC-157 has demonstrated the ability to counteract dopamine system dysregulation, restore dopamine receptor sensitivity, and support serotonergic pathway integrity in preclinical models of stress-induced dysfunction. For anyone whose cognitive performance has been degraded by high-stress periods, chronic sleep deprivation, or psychological trauma, this pathway is directly relevant.

BPC-157 also promotes peripheral nerve regeneration — an effect that extends to the enteric nervous system (the gut's neural network), creating a bidirectional benefit through the gut-brain axis. Restoration of enteric nervous system integrity improves vagal tone and neurotransmitter precursor availability, both of which contribute to central cognitive function.